• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close

Biological assay development and validation

CONTACT US

Biological assays are experimental methods for assessing the presence, localization, or biological activity of a substance in living cells and biological matrices. Such methods are essential to biological science and technology. Many applications require novel assays to answer new questions, and existing assays must be implemented in a way that is robust and reproducible. Assay development and validation are routinely performed at SRI. Our scientists develop biological assays for application to basic science, drug discovery and development, and creation of diagnostics.

Biological assay types

Cell-based assays

Measurements made on cultured cells provide information about the chemical and physical state of the cells. These assays probe the biological effects of changing physiological conditions or added agents such as drugs or toxins. SRI researchers use cell-based assays to identify new therapeutic targets, discover new drugs, test chemicals for toxicity, detect pathogen infection, engineer cell function, and study the normal mechanisms underlying cell behavior.

SRI has extensive experience developing cell-based assays that address a wide range of biological questions and challenges:

  • Cell viability/compound cytotoxicity assays
  • Apoptosis
  • RNAi-based target validation
  • Cell proliferation
  • Autophagy
  • Intracellular pathogen assays
  • Novel fluorescence probes

Functional genomics and proteomics

Functional genomics is a field of biology that focuses on the expression and function of genes and their protein products. It comprises methods to study and characterize the molecular interactions that translate into structure, function, and behavior of cells and organisms. Tools to measure many products of gene expression in parallel are essential to this area of research. They include proteomics methods for characterizing complex collections of proteins.

SRI’s experience developing assays for functional genomics and proteomics includes:

  • Shotgun and quantitative approaches
  • Characterization of post-translational modifications
  • Gene expression analysis using mRNA arrays and miRNA arrays

  • Gene editing with CRISPR/Cas 9
  • SiRNA
  • Gene expression analysis using reporter genes

Imaging and analysis

Imaging technologies enable scientists to see biological phenomena that are invisible to the unaided human eye. Biologists at SRI apply imaging and image analysis methods to a wide range of investigations, including detecting and locating proteins within living cells and tissues, visualizing the internal structures and biochemistry of living organisms, and visualizing biological structures that are simply too small to see.

SRI’s expertise in biological imaging and image analysis includes:

  • Specialized histology
  • High content imaging
  • Transmission and scanning electron microscopy
  • Noninvasive fluorescence, bioluminescence, and X-ray imaging

  • Immunocytochemistry
  • Confocal and Fluorescence microscopy
  • Quantitative image analysis

Clinical laboratory analyses

SRI’s Clinical Analysis Laboratory is fully compliant with FDA Good Laboratory Practice (GLP) regulations and uses state-of-the-art instrumentation and data management to offer full capabilities for standard and specialized services for both human and veterinary clinical research samples.

Our capabilities include:

  • Broad range of routine and specialized hematology and clinical chemistry services
  • Routine and specialized analyses for coagulation and urinalysis parameters
  • Recently FDA- and EMEA-approved biomarkers of toxicity for kidney, liver, muscle, and other target organs

Discovery ADMET and in vitro metabolism

SRI is a leader in the development and application of in vitro models for ADMET evaluations (ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity). Obtaining data on potential toxicity early in the development process can help you make informed decisions to move promising leads forward and exclude liabilities. Our staff has extensive experience in elucidating tissue-specific mechanisms of toxicity for various species and organs. We pioneered the application of human tissue preparations to predicting interspecies differences in drug metabolism, potential drug interactions, and human drug metabolizing enzymes.

Predictive ADMET

  • Membrane permeability: PAMPA, Caco-2, MDCK cells
  • Metabolic stability: liver or small intestine microsomes
  • Plasma stability
  • Cytochrome P450 (CYP) inhibition
  • Plasma protein binding
  • p-Glycoprotein substrate assays
  • In vivo pharmacokinetic screens
  • High-throughput LC-MS/MS quantitation
  • First in vivo dose to mice

In vitro metabolism and toxicity

  • Metabolite profiling and identification
  • Reaction phenotyping: CYP, UGT, SULT
  • Drug-drug interactions
  • Peroxisome proliferation
  • Co-incubation screens
  • Therapeutic index estimations
  • Cytotoxicity and hepatotoxicity screening
  • Mini-Ames mutagenicity screen
  • Mini I (hERG) cardiotox liability screen

Drug metabolism and pharmacokinetics

SRI offers comprehensive drug metabolism and pharmacokinetic (DMPK) services to meet your needs. We give you access to a complete range of capabilities, beginning with dose administration followed by full-service bioanalytical support and pharmacokinetic data analysis and interpretation. We offer PK studies that fully comply with U.S. FDA GLP regulations.

Bioanalytical quantitative methods
  • Bioanalytical method development and validation
    • Small molecules: LC/ MS/MS, GC-MS, HPLC with UV, fluorescence, radiochemical detection
    • Proteins: ELISA, antibody titer
  • Quantitative PCR
    • DNA/RNA test article, e.g., plasmid, virus
    • Biodistribution, persistence, integration
    • mRNA expression levels
    • Subcellular localization
    • Chromosomal integration

Pharmacokinetic and pharmacodynamic analyses
  • Single-dose pharmacokinetics
  • Bioavailability
  • Multiple-dose pharmacokinetics
  • Drug accumulation
  • Metabolite identification
  • WinNonlinTM compartmental and noncompartmental analysis
  • PK/PD interpretation
  • Bioequivalence
  • Allometric estimations
  • Formulation screening

Comprehensive ADME
  • Absorption and clearance
  • Tissue distribution
  • DNA/RNA biodistribution, persistence, integration
  • Interspecies comparative metabolism
  • Metabolite profile
  • Excretion and mass balance
  • Radiolabeled drug synthesis

Immunology services

SRI International Immunology Services Facility provides quality services in the area of immunology, virology, autoimmunity and inflammation that covers all stages of drug discovery and development. With state-of-the-art instruments, laboratory, and validated software systems, the Immunology team offers customized services to meet clients’ needs which includes but is not limited to assay development and validation for preclinical and clinical studies, as well as preclinical and clinical sample analysis.

  • Assessment of immunogenicity (flow cytometry, ELISA, and ELISPOT)
    • Cellular and humoral
    • Antidrug antibody (ADA)
    • Neutralizing antibody (NAb)
  • Measurement of large molecules in biological fluids
    • Measurement of antibodies, proteins, and peptides in biological fluids
    • Measurement of vaccine efficacy, potency and stability
    • Immunotoxicology evaluation
  • Measurement of cytokines
  • Biomarker analysis (flow cytometry and ELISA)
  • Receptor binding and cell-based assays

Published work

  • Call to action: an open-source pipeline for standardized performance evaluation of sleep-tracking technology  

    February 22, 2023

    There is an urgent need for standardized, rigorous, and open-source tools that the community can access in a timely manner to systematically evaluate the performance of new technology for measuring sleep.

  • Multi-atlas thalamic nuclei segmentation on standard T1-weighed MRI with application to normal aging 

    February 22, 2023

    The threefold aims of this study were to validate the use of a modified thalamic nuclei segmentation method on standard T1 MRI data, to apply this method to quantify age-related volume declines, and to test functional meaningfulness by predicting performance on motor testing

  • A prospective study revealing a compounded burden of COVID-19, sex, and clinical diagnosis of alcohol use disorder and HIV infection on quality of life, anxiety, and alcohol use 

    February 22, 2023

    Participants were drawn from our ongoing longitudinal studies of people with HIV infection, alcohol use disorder (AUD), HIV + AUD comorbidity, and controls.

  • Prior test experience confounds longitudinal tracking of adolescent cognitive and motor development 

    February 22, 2023

    We measured change in cognitive and motor abilities over four test sessions in participants from the National Consortium on Alcohol and NeuroDevelopment in Adolescence study.

  • It’s Not Just About the Hot Flashes: Menopausal Hormone Changes and Disrupted Sleep 

    January 22, 2023

    Sleep disturbances are common during the menopausal transition, being reported by more than half of midlife women

  • Adolescent alcohol use is linked to disruptions in age-appropriate cortical thinning: an unsupervised machine learning approach 

    January 22, 2023

    In this study, adolescents from the NCANDA study who endorsed little to no alcohol use at baseline were assessed with structural magnetic resonance imaging and followed longitudinally at four yearly intervals.

Some of our experts

wei-zhou-bio-pic

Wei Zhou

Research Scientist, Webb Laboratory, Medicinal & Synthetic Chemistry

Mike McGuire Benchside bio pic

Michael McGuire

Research Scientist, Brown Laboratory, Macromolecular Sciences

carol green bio pic

Carol Green

Senior Director, Preclinical Development

naseem-chini-bio-pic

Naseem Chini

Director, Clinical Analysis Laboratory

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International